Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bio Green Med Solution, Inc.CYCC · Entity 8225 | Director | June 14, 2022 | June 16, 2022 |
| DETERMINE, INC.DTRM · Entity 158391 | Director | November 14, 2017 | November 15, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bio Green Med Solution, Inc.
Report date June 14, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,196 |
Reported balance
After 2022-06-14 transaction · row 1
1 source rowRow 1 · 2022-06-14 · Grant · Acquired 15,822 · Balance 18,196 F1: The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2032-06-14 | Direct | 31,645 |
Reported balance
After 2022-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-14 · Grant · Acquired 31,645 · Balance 31,645 F2: These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023.
F2: These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.
DETERMINE, INC.
Report date November 14, 2017 · Filed November 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 268,860 |
Reported balance
After 2017-11-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-11-14 · Grant · Acquired 22,099 · Balance 268,860 F1: Consists of Restricted Stock Units (RSUs) granted pursuant to the Company's Compensation Program for Non-Employee Directors, which RSUs vest on November 14, 2018, subject to the director's continued service on the Board of Directors, with immediate full vesting in the event of a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of Restricted Stock Units (RSUs) granted pursuant to the Company's Compensation Program for Non-Employee Directors, which RSUs vest on November 14, 2018, subject to the director's continued service on the Board of Directors, with immediate full vesting in the event of a Change of Control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2022 Filed Jun 16, 2022 20:11 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 31,645 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-22-071898 · tm2218645-4_4seq1.xml · derivative · entry 2 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,645 Underlying: Common Stock · 31,645 shares Expires 2032-06-14 F2 · price: These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:11 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantCommon Stock | 15,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071898 · tm2218645-4_4seq1.xml · nonDerivative · entry 1 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,196 F1 · shares: The reporting person received an award of 15,822 restricted stock units on June 14, 2022, which shall vest in full on June 14, 2023. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:08 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 4,748 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082600 · tm2119990d4_4.xml · derivative · entry 2 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,748 Underlying: Common Stock · 4,748 shares Expires 2031-06-15 F2 · price: These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:08 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantCommon Stock | 2,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082600 · tm2119990d4_4.xml · nonDerivative · entry 1 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374 F1 · shares: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 22:51 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001104659-20-078132 · tm2023597-8_4.xml · derivative · entry 1 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-06-25 F1 · price: These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:37 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001144204-19-029256 · tv522821_form4.xml · derivative · entry 1 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2029-05-29 F1 · price: These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 21:33 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 8,576 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001144204-18-032717 · tv495791_form4.xml · derivative · entry 1 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,576 Underlying: Common Stock · 8,576 shares Expires 2028-05-31 F1 · price: These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| November 14, 2017 Filed Nov 15, 2017 13:36 UTC | DETERMINE, INC. DTRM · Entity 158391 | GrantCommon Stock | 22,099 | $1.81 | $39,999.19 |
DisclosureSEC source: 0001437749-17-019445 · rdgdoc.xml · nonDerivative · entry 1 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,860 F1 · security: Consists of Restricted Stock Units (RSUs) granted pursuant to the Company's Compensation Program for Non-Employee Directors, which RSUs vest on November 14, 2018, subject to the director's continued service on the Board of Directors, with immediate full vesting in the event of a Change of Control. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 21:06 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001571049-17-005587 · t1701732_x5-f4.xml · derivative · entry 1 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-05-30 F1 · price: These options were granted to Mr. Sems for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:25 UTC | DETERMINE, INC. DTRM · Entity 158391 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001437749-17-002728 · rdgdoc.xml · derivative · entry 2 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,333 Underlying: Common Stock · 5,000 shares Expires 2027-02-14 F2 · derivative.exercise_date: Options vest in three equal installments on August 11, 2017, August 11, 2018 and August 11, 2019. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:25 UTC | DETERMINE, INC. DTRM · Entity 158391 | GrantCommon Stock | 14,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-002728 · rdgdoc.xml · nonDerivative · entry 1 Sems Lloyd · CIK 0001436850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,761 F1 · security: Consists of Restricted Stock Units that vest on August 11, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.